SI-BONE Stock Forecast, Price & News

-4.49 (-14.84 %)
(As of 08/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.35 million shs
Average Volume276,393 shs
Market Capitalization$845.57 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SIBN News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

SI-BONE logo


SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and Internationally. The company offers iFuse, a minimally invasive surgical implant system, which is intended to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.40 out of 5 stars

Medical Sector

167th out of 1,309 stocks

Surgical & Medical Instruments Industry

17th out of 121 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

SI-BONE (NASDAQ:SIBN) Frequently Asked Questions

Is SI-BONE a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SI-BONE stock.
View analyst ratings for SI-BONE
or view top-rated stocks.

What stocks does MarketBeat like better than SI-BONE?

Wall Street analysts have given SI-BONE a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SI-BONE wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is SI-BONE's next earnings date?

SI-BONE is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for SI-BONE

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) announced its quarterly earnings results on Sunday, August, 1st. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.03. SI-BONE had a negative trailing twelve-month return on equity of 31.92% and a negative net margin of 56.06%.
View SI-BONE's earnings history

How has SI-BONE's stock price been impacted by COVID-19 (Coronavirus)?

SI-BONE's stock was trading at $15.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SIBN stock has increased by 68.2% and is now trading at $25.77.
View which stocks have been most impacted by COVID-19

What guidance has SI-BONE issued on next quarter's earnings?

SI-BONE issued an update on its FY 2021 earnings guidance on Monday, August, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $92 million-$94 million, compared to the consensus revenue estimate of $93.69 million.

What price target have analysts set for SIBN?

5 brokers have issued 12-month price targets for SI-BONE's shares. Their forecasts range from $35.00 to $43.00. On average, they expect SI-BONE's stock price to reach $39.67 in the next year. This suggests a possible upside of 53.9% from the stock's current price.
View analysts' price targets for SI-BONE
or view top-rated stocks among Wall Street analysts.

Who are SI-BONE's key executives?

SI-BONE's management team includes the following people:
  • Ms. Laura A. Francis, CEO & Director (Age 54, Pay $617.85k)
  • Mr. Anthony J. Recupero, Pres of Commercial Operations (Age 62, Pay $588.58k)
  • Mr. Anshul Maheshwari, Chief Financial Officer
  • Mr. Michael A. Pisetsky, Sr. VP of Operations & Admin., Sec. and Chief Legal Officer (Age 43)
  • Dr. Scott A. Yerby, Sr. VP of Engineering & CTO (Age 53)
  • Mr. Joseph W. Powers, VP of Corp. Marketing (Age 61)
  • Dr. W. Carlton Reckling, Chief Medical Officer & VP of Medical Affairs (Age 59)
  • Mr. Nikolas F. Kerr, Sr. VP of Product, Strategy & Bus. Devel. (Age 49)
  • Ms. Joyce Goto, VP & Corp. Controller (Age 47)

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE CEO Jeffrey Dunn on Jeffrey Dunn has an approval rating of 41% among SI-BONE's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of SI-BONE's key competitors?

What other stocks do shareholders of SI-BONE own?

When did SI-BONE IPO?

(SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is SI-BONE's stock symbol?

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

Who are SI-BONE's major shareholders?

SI-BONE's stock is owned by a number of retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (0.72%), Calamos Advisors LLC (0.13%), Ellsworth Advisors LLC (0.04%), Arizona State Retirement System (0.02%) and Brinker Capital Investments LLC (0.02%). Company insiders that own SI-BONE stock include Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky, Scott A Yerby, Skyline Venture Partners V Lp and W Carlton Reckling.
View institutional ownership trends for SI-BONE

Which major investors are selling SI-BONE stock?

SIBN stock was sold by a variety of institutional investors in the last quarter, including Calamos Advisors LLC, and Arizona State Retirement System. Company insiders that have sold SI-BONE company stock in the last year include Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeryl L Hilleman, John Gordon Freund, Laura Francis, and Michael A Pisetsky.
View insider buying and selling activity for SI-BONE
or view top insider-selling stocks.

Which major investors are buying SI-BONE stock?

SIBN stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Brinker Capital Investments LLC, and Ellsworth Advisors LLC.
View insider buying and selling activity for SI-BONE
or or view top insider-buying stocks.

How do I buy shares of SI-BONE?

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SI-BONE's stock price today?

One share of SIBN stock can currently be purchased for approximately $25.77.

How much money does SI-BONE make?

SI-BONE has a market capitalization of $845.57 million and generates $73.39 million in revenue each year. The company earns $-43,700,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

How many employees does SI-BONE have?

SI-BONE employs 295 workers across the globe.

What is SI-BONE's official website?

The official website for SI-BONE is

Where are SI-BONE's headquarters?

SI-BONE is headquartered at 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050.

How can I contact SI-BONE?

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company can be reached via phone at 408-207-0700 or via email at [email protected]

This page was last updated on 8/3/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.